Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019)
Vir Biotechnology recorded quarterly Preferred Stock Liabilities of $636.6 million in Q3 2019, little changed quarter-over-quarter from $636.6 million in Q2 2019, and up 105.93% year-over-year from $309.1 million in Q3 2018.
Vir Biotechnology's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $636.6 million for Q3 2019.
- In Q3 2019, Preferred Stock Liabilities rose 105.93% year-over-year to $636.6 million; the TTM figure through Sep 2019 stood at $636.6 million (up 105.93% YoY), while the FY2018 annual figure was $309.1 million, up 5.68% from the prior year.
- Preferred Stock Liabilities came in at $636.6 million for Q3 2019 at Vir Biotechnology, roughly flat from $636.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $636.6 million in Q2 2019 to a low of $307.2 million in Q2 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 636.61 Mn |
| Jun 30, 2019 | 636.61 Mn |
| Dec 31, 2018 | 309.14 Mn |
| Sep 30, 2018 | 309.14 Mn |
| Jun 30, 2018 | 307.19 Mn |